Infect Chemother.  2016 Sep;48(3):209-215. 10.3947/ic.2016.48.3.209.

Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections

• Kim YK
• Jung JA
• Choi HK
• Bae IG
• Choi WS
• Hur J
• Jin SJ
• Kim SW
• Kwon KT
• Lee SR
• Shin JG
• Kiem S
• Pharmacokinetics-Pharmacodynamics of Antibiotics Working Group under Korean Society for Chemotherapy

• KMID: 2466433
• DOI: http://doi.org/10.3947/ic.2016.48.3.209

Abstract

BACKGROUND
For more effective and safer usage of antibiotics, the dosing strategy should be individualized based on the patients' characteristics, including race. The aim of this study was to investigate the population pharmacokinetic (PK) profiles of piperacillin and tazobactam in Korean patients with acute infections.
MATERIALS AND METHODS
At least four consecutive 2/0.25 g or 4/0.5 g doses of piperacillin/tazobactam (TZP) were intravenously infused over 1 h every 8 h for patients with creatinine clearance (CL(cr)) ≤50 ml/min or CL(cr) >50 mL/min, respectively. Blood samples from 33 patients at a steady-state were taken pre-dose and at 0 min, 30 min, and 4-6 h after the fourth infusion. The population PK analysis was conducted using a non-linear mixed-effects method. A likelihood ratio test was used to select significant covariates, with significance levels of P <0.05 for selection and P <0.01 for elimination.
RESULTS
Both piperacillin PK and tazobactam PK were well described by a two-compartment model with first-order elimination. Creatinine clearance and body weight, as covariates on clearance (CL) and volume of central compartment (V1), were selected among the covariates possibly affecting PK parameters of both drugs. CL was defined as CL = 2.9 + 4.03 × CL(cr)/47 for piperacillin and CL = 1.76 + 4.81 × CL(cr)/47 for tazobactam. V1 was defined as V1 = 19.5 × weight/60 for piperacillin and V1 = 22.6 × weight/60 for tazobactam.
CONCLUSION
The PK profiles of TZP at a steady-state in Korean patients with acute infections were well described by a two-compartment model with first-order elimination. Both piperacillin and tazobactam clearances were significantly influenced by creatinine clearance.

Keyword

Piperacillin; Tazobactam; Race; Population pharmacokinetics; Clearance

MeSH Terms

Anti-Bacterial Agents
Body Weight
Continental Population Groups
Creatinine
Humans
Methods
Piperacillin
Anti-Bacterial Agents
Creatinine
Piperacillin

Figure

• 

  Figure 1 Goodness of fit plots for the final pharmacokinetic models for piperacillin (4 figures of the upper panel) and tazobactam (4 figures of the lower panel). The grey line indicates the line of identity; the red line indicates the linear regression line. CWRES: conditional weighted residual.

• 

  Figure 2 Visual predictive check for the final piperacillin pharmacokinetic model, simulation of 2,000 data sets, using the final pharmacokinetic parameter estimates. Open circles indicate observed concentrations; the red full line indicates the median value; the lower and upper red dotted lines indicate the 2.5th and 97.5th predicted value, respectively.

Reference

1. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacilin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007; 5:365–383.

2. Maltezou HC, Nikolaidis P, Lebesii E, Dimitriou L, Androulakakis E, Kafetzis DA. Piperacillin/tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 2001; 20:643–646.

3. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D’Inzeo T, Fadda G, Cauda R, Spanu T. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007; 51:1987–1994.

4. Peralta G, Lamelo M, Alvarez-García P, Velasco M, Delgado A, Horcajada JP, Montero M, Roiz MP, Fariñas MC, Alonso J, Martínez LM, Gutiérrez-Macías A, Alava JA, Rodríguez A, Fleites A, Navarro V, Sirvent E, Capdevila JA; SEMI- BLEE STUDY GROUP. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp bacteremia. A multicentric cohort study. BMC Infect Dis. 2012; 12:245.

5. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis. 1998; 27:10–22.

6. Mckinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008; 31:345–351.

7. Lodise TP, Lomaestro BM, Drusano GL; Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamics concepts into clinical practice: focus onββ -lactam antibiotics: insights form the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006; 26:1320–1332.

8. Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing refimens in hospitalized patients. Antimicrob Agents Chemother. 2010; 54:460–465.

9. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J. Continous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013; 56:236–244.

10. Roberts JA, Ulldemolins M, Roberts MS, McWhinney BC, Ungerer J, Paterson DL, Lipman J. Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010; 36:332–339.

11. Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci. 1997; 86:1328–1333.

12. Chen ML. Ethnic or racial differences revisited: impact of dosage regimen form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2006; 45:957–964.

13. Jeon S, Han S, Lee J, Hong T, Paek J, Woo H, Yim DS. Population pharmacokinetic analysis of piperacillin in burn patients. Antimicrob Agents Chemother. 2014; 58:3744–3751.

14. Oh KH, Kim C, Lee H, Lee H, Jung JY, Kim NJ, Yu KS, Shin KH, Jang IJ, Ahn C. Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration. Antimicrob Agents Chemother. 2009; 53:3266–3268.

15. Kiem S, Ryu SM, Lee YM, Schentag JJ, Kim YW, Kim HK, Jang HJ, Joo YD, Jin K, Shin JG, Ghim JL. Population pharmacokinetics of levofloxacin in Korean patients. J Chemother. 2016; 28:308–313.

16. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother. 2005; 56:388–395.

17. Felton TW, Roberts JA, Lodise TP, Guilder MV, Boselli E, Neely MN, Hope WW. Indivisualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother. 2014; 58:4094–4102.

18. Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol. 2010; 6:1017–1031.

19. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000; 39:215–231.

20. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet. 1994; 26:292–307.

21. Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents. 2013; 41:52–56.

22. Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. J Clin Pharmacol. 2015; 55:899–908.

23. Tamma PD, Turnbull AE, Milstone AM, Hsu AJ, Carroll KC, Cosgrove SE. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia? Clin Infect Dis. 2012; 55:799–806.

24. Karino F, Nishimura N, Ishihara N, Moriyama H, Miura K, Hamaguchi S, Sutani A, Kuraki T, Morikawa N. Nephrotoxicity induced by piperacillin-tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia. Biol Pharm Bull. 2014; 37:1971–1976.

25. Huang WT, Hsu YJ, Chu PL, Lin SH. Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure. Infection. 2009; 37:374–376.